Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s
Business
Archived
•
September 25, 2026
•
7 views
As Novo works to turn itself around, some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market.
Source: CNBC Top | https://search.cnbc.com/rs/search/combinedcms/view.xml?partnerId=wrss01&id=100003114 - Read Original
Discussion (0)
Please log in to post a comment.
No comments yet. Be the first to share your thoughts!



